466 related articles for article (PubMed ID: 28233660)
21. Comparing the impact of increasing condom use or HIV pre-exposure prophylaxis (PrEP) use among female sex workers.
Mukandavire Z; Mitchell KM; Vickerman P
Epidemics; 2016 Mar; 14():62-70. PubMed ID: 26972515
[TBL] [Abstract][Full Text] [Related]
22. Time to Scale Up Preexposure Prophylaxis Beyond the Highest-Risk Populations? Modeling Insights From High-Risk Women in Sub-Saharan Africa.
Grant H; Gomez GB; Kripke K; Barnabas RV; Watts C; Medley GF; Mukandavire Z
Sex Transm Dis; 2020 Nov; 47(11):767-777. PubMed ID: 33044426
[TBL] [Abstract][Full Text] [Related]
23. Using a HIV prevention cascade for identifying missed opportunities in PrEP delivery in Kenya: results from a programmatic surveillance study.
Were D; Musau A; Mutegi J; Ongwen P; Manguro G; Kamau M; Marwa T; Gwaro H; Mukui I; Plotkin M; Reed J
J Int AIDS Soc; 2020 Jun; 23 Suppl 3(Suppl 3):e25537. PubMed ID: 32602658
[TBL] [Abstract][Full Text] [Related]
24. Cost-effectiveness analysis of pre-exposure prophylaxis for HIV-1 prevention in the Netherlands: a mathematical modelling study.
Nichols BE; Boucher CAB; van der Valk M; Rijnders BJA; van de Vijver DAMC
Lancet Infect Dis; 2016 Dec; 16(12):1423-1429. PubMed ID: 27665989
[TBL] [Abstract][Full Text] [Related]
25. Introducing pre-exposure prophylaxis to prevent HIV acquisition among men who have sex with men in Sweden: insights from a mathematical pair formation model.
Hansson D; Strömdahl S; Leung KY; Britton T
BMJ Open; 2020 Feb; 10(2):e033852. PubMed ID: 32029492
[TBL] [Abstract][Full Text] [Related]
26. Portfolios of biomedical HIV interventions in South Africa: a cost-effectiveness analysis.
Long EF; Stavert RR
J Gen Intern Med; 2013 Oct; 28(10):1294-301. PubMed ID: 23588668
[TBL] [Abstract][Full Text] [Related]
27. The new role of antiretrovirals in combination HIV prevention: a mathematical modelling analysis.
Cremin I; Alsallaq R; Dybul M; Piot P; Garnett G; Hallett TB
AIDS; 2013 Jan; 27(3):447-58. PubMed ID: 23296196
[TBL] [Abstract][Full Text] [Related]
28. Princess PrEP program: the first key population-led model to deliver pre-exposure prophylaxis to key populations by key populations in Thailand.
Phanuphak N; Sungsing T; Jantarapakde J; Pengnonyang S; Trachunthong D; Mingkwanrungruang P; Sirisakyot W; Phiayura P; Seekaew P; Panpet P; Meekrua P; Praweprai N; Suwan F; Sangtong S; Brutrat P; Wongsri T; Na Nakorn PR; Mills S; Avery M; Vannakit R; Phanuphak P
Sex Health; 2018 Nov; 15(6):542-555. PubMed ID: 30249317
[TBL] [Abstract][Full Text] [Related]
29. HIV pre-exposure prophylaxis in transgender women: a subgroup analysis of the iPrEx trial.
Deutsch MB; Glidden DV; Sevelius J; Keatley J; McMahan V; Guanira J; Kallas EG; Chariyalertsak S; Grant RM;
Lancet HIV; 2015 Dec; 2(12):e512-9. PubMed ID: 26614965
[TBL] [Abstract][Full Text] [Related]
30. Competing biomedical HIV prevention strategies: potential cost-effectiveness of HIV vaccines and PrEP in Seattle, WA.
Adamson B; Garrison L; Barnabas RV; Carlson JJ; Kublin J; Dimitrov D
J Int AIDS Soc; 2019 Aug; 22(8):e25373. PubMed ID: 31402591
[TBL] [Abstract][Full Text] [Related]
31. Estimates of the size of key populations at risk for HIV infection: men who have sex with men, female sex workers and injecting drug users in Nairobi, Kenya.
Okal J; Geibel S; Muraguri N; Musyoki H; Tun W; Broz D; Kuria D; Kim A; Oluoch T; Raymond HF
Sex Transm Infect; 2013 Aug; 89(5):366-71. PubMed ID: 23761166
[TBL] [Abstract][Full Text] [Related]
32. Modelling the Epidemiological Impact and Cost-Effectiveness of PrEP for HIV Transmission in MSM in China.
Zhang L; Peng P; Wu Y; Ma X; Soe NN; Huang X; Wu H; Markowitz M; Meyers K
AIDS Behav; 2019 Feb; 23(2):523-533. PubMed ID: 29971734
[TBL] [Abstract][Full Text] [Related]
33. Towards a fair consideration of PrEP as part of combination HIV prevention in Latin America.
Ravasi G; Grinsztejn B; Baruch R; Guanira JV; Luque R; Cáceres CF; Ghidinelli M
J Int AIDS Soc; 2016; 19(7(Suppl 6)):21113. PubMed ID: 27760687
[TBL] [Abstract][Full Text] [Related]
34. The cost-effectiveness of oral HIV pre-exposure prophylaxis and early antiretroviral therapy in the presence of drug resistance among men who have sex with men in San Francisco.
Shen M; Xiao Y; Rong L; Meyers LA; Bellan SE
BMC Med; 2018 Apr; 16(1):58. PubMed ID: 29688862
[TBL] [Abstract][Full Text] [Related]
35. Epidemiological impact and cost-effectiveness of providing long-acting pre-exposure prophylaxis to injectable contraceptive users for HIV prevention in South Africa: a modelling study.
van Vliet MM; Hendrickson C; Nichols BE; Boucher CA; Peters RP; van de Vijver DA
J Int AIDS Soc; 2019 Dec; 22(12):e25427. PubMed ID: 31855323
[TBL] [Abstract][Full Text] [Related]
36. The impact and cost-effectiveness of combined HIV prevention scenarios among transgender women sex-workers in Lima, Peru: a mathematical modelling study.
Bórquez A; Guanira JV; Revill P; Caballero P; Silva-Santisteban A; Kelly S; Salazar X; Bracamonte P; Minaya P; Hallett TB; Cáceres CF
Lancet Public Health; 2019 Mar; 4(3):e127-e136. PubMed ID: 30683587
[TBL] [Abstract][Full Text] [Related]
37. High HIV risk in a cohort of male sex workers from Nairobi, Kenya.
McKinnon LR; Gakii G; Juno JA; Izulla P; Munyao J; Ireri N; Kariuki CW; Shaw SY; Nagelkerke NJ; Gelmon L; Musyoki H; Muraguri N; Kaul R; Lorway R; Kimani J
Sex Transm Infect; 2014 May; 90(3):237-42. PubMed ID: 24337729
[TBL] [Abstract][Full Text] [Related]
38. Can we afford to offer pre-exposure prophylaxis to MSM in Catalonia? Cost-effectiveness analysis and budget impact assessment.
Reyes-Urueña J; Campbell C; Diez E; Ortún V; Casabona J
AIDS Care; 2018 Jun; 30(6):784-792. PubMed ID: 29262694
[TBL] [Abstract][Full Text] [Related]
39. A Qualitative Study of Medical Mistrust, Perceived Discrimination, and Risk Behavior Disclosure to Clinicians by U.S. Male Sex Workers and Other Men Who Have Sex with Men: Implications for Biomedical HIV Prevention.
Underhill K; Morrow KM; Colleran C; Holcomb R; Calabrese SK; Operario D; Galárraga O; Mayer KH
J Urban Health; 2015 Aug; 92(4):667-86. PubMed ID: 25930083
[TBL] [Abstract][Full Text] [Related]
40. Predicted effects of the introduction of long-acting injectable cabotegravir pre-exposure prophylaxis in sub-Saharan Africa: a modelling study.
Smith J; Bansi-Matharu L; Cambiano V; Dimitrov D; Bershteyn A; van de Vijver D; Kripke K; Revill P; Boily MC; Meyer-Rath G; Taramusi I; Lundgren JD; van Oosterhout JJ; Kuritzkes D; Schaefer R; Siedner MJ; Schapiro J; Delany-Moretlwe S; Landovitz RJ; Flexner C; Jordan M; Venter F; Radebe M; Ripin D; Jenkins S; Resar D; Amole C; Shahmanesh M; Gupta RK; Raizes E; Johnson C; Inzaule S; Shafer R; Warren M; Stansfield S; Paredes R; Phillips AN;
Lancet HIV; 2023 Apr; 10(4):e254-e265. PubMed ID: 36642087
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
